TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04738045

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remdesivir
Description: Remdesivir will be administrated intravenously (IV) at a dose of 200 mg loading dose then 100 mg once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ Ritonavir and Remdesivir combination
Description: Remdesivir will be administrated intravenously (IV) at a dose of 200 mg loading dose then 100 mg once daily and Lopinavir / ritonavir at a dose of 400 /100 once daily for 5 days
Study: NCT00091390

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High Dose brachytherapy boost
Description: 19 Gy in two fractions (on day of placement and 6-24 hours later) before or after external beam radiotherapy, such that all study treatment occurs within 8 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy
Description: 45 Gy as 1.8 Gy five days a week for five weeks.
Study: NCT01322607

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: High-intensity Treadmill Exercise
Description: High-intensity treadmill walking program

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Low-intensity Lifestyle Intervention
Description: A low-intensity lifestyle intervention targeted towards group exercises incorporating balance, coordination, and strength.
Study: NCT02289755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALLN-177
Description: ALLN-177 is orally administered oxalate decarboxylase (OxDc). The goal of oral therapy with ALLN-177 is to enzymatically degrade both dietary oxalate and endogenously produced oxalate secreted in the gastrointestinal tract resulting in decreased absorption and reduced urinary oxalate excretion.
Study: NCT00942877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2171
Description: Cediranib (AZD2171), a vascular endothelial growth factor (VEGF)/KIT tyrosine kinase inhibitor, has demonstrated antitumor activity in early phase clinical trials in adult and pediatric patients with Alveolar Soft Part Sarcoma (ASPS).
Study: NCT00739297

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: montelukast
Description: 5 Period, Cross-over, Dose-Ranging study. Period I: no treatment. Periods II-V: Single-dose administration of inhaled montelukast (using doses as low as 25 mcg, to as high as 1000 mcg), or montelukast placebo. Two puffs of albuterol or albuterol placebo will be given four hours after montelukast/montelukast placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: montelukast
Description: 5 Period, Cross-over, Dose-Ranging study. Period I: no treatment. Periods II-V: Single-dose administration of inhaled montelukast (using doses as low as 25 mcg, to as high as 1000 mcg), or montelukast placebo. Two puffs of albuterol or albuterol placebo will be given four hours after montelukast/montelukast placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: montelukast
Description: 5 Period, Cross-over, Dose-Ranging study. Period I: no treatment. Periods II-V: Single-dose administration of inhaled montelukast (using doses as low as 25 mcg, to as high as 1000 mcg), or montelukast placebo. Two puffs of albuterol or albuterol placebo will be given four hours after montelukast/montelukast placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: montelukast
Description: 5 Period, Cross-over, Dose-Ranging study. Period I: no treatment. Periods II-V: Single-dose administration of inhaled montelukast (using doses as low as 25 mcg, to as high as 1000 mcg), or montelukast placebo. Two puffs of albuterol or albuterol placebo will be given four hours after montelukast/montelukast placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: 5 Period, Cross-over, Dose-Ranging study. Period I: no treatment. Periods II-V: Single-dose administration of inhaled montelukast (using doses as low as 25 mcg, to as high as 1000 mcg), or montelukast placebo. Two puffs of albuterol or albuterol placebo will be given four hours after montelukast/montelukast placebo.
Study: NCT01858428

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiovascular Ingenuity (CVI) Paclitaxel-coated Percutaneous Transluminal Angioplasty Balloon Catheter
Description: The CVI Paclitaxel-coated PTA Catheter is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien, Plymouth, MN 55441, USA) coated with paclitaxel using a proprietary carrier.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EverCross Percutaneous Transluminal Balloon Catheter
Description: The control device is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien, Plymouth, MN 55441, USA).
Study: NCT03332004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: 0.25 mg /(kg BW) Indocyanine Green PULSION® - PULSION Medical Systems were administered intravenously
Study: NCT02335450

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: The participant will describe their unique physical activity challenges and their physical activity goals with the physical therapist. Using the technique of motivational interviewing, the physical therapist will work with the participant to help identify potential solutions to challenges and set realistic activity goals for the next week. Each week, the participant and the physical therapist will review the previous week's activity data, and the participant's reports of any challenges or problems they encountered in meeting their physical activity goals the previous week. The participant will identify new activity goals for the next week.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wristband physical activity monitor
Description: The participant will wear a Fitbit wristband which will track the participant's daily steps and minutes of physical activity.
Study: NCT00758303

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose TRIA-662
Description: One Capsule 3 times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Dose TRIA-662
Description: 3 Capsules 3 times daily
Study: NCT01151618

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respironics Synchrony ventilator (Non Invasive Ventilation)
Description: Non Invasive Ventilation using forced oscillation technique (FOT)
Study: NCT02480634

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid
Description: Comparison the curative effect of the high does radiotherapy and low does therapy after use the Zoledronic acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Comparison the curative effect of the high does radiotherapy and low does therapy after use the Zoledronic acid

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: High dose：30Gy/10f Low dose：15Gy/5f

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: High dose：30Gy/10f Low dose：15Gy/5f
Study: NCT00210639

Intervention type: DRUG
Intervention: No intervention
Description: This is an observational study. Participants rceiving dosing regimen from the respective Phase 3 levofloxacin clinical studies will be observed in this study.

Intervention type: DRUG
Intervention: No intervention
Description: This is an observational study. Participants rceiving dosing regimen from the respective Phase 3 levofloxacin clinical studies will be observed in this study.
Study: NCT04175587

Intervention type: DRUG
Group type: OTHER
Intervention: Compound Realgar-Indigo Naturalis Formula Plus Retinoic Acid
Description: Randomization is done centrally according to trial centers Eligible patients are randomly assigned (2:1) to the Treatment Group or the Control Group, with a 24-month follow-up.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound Realgar-Indigo Naturalis Formula Plus Retinoic Acid
Description: Randomization is done centrally according to trial centers Eligible patients are randomly assigned (2:1) to the Treatment Group or the Control Group, with a 24-month follow-up.
Study: NCT04621617

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin
Description: Human albumin will be administered by intravenous infusion at a dose of 1.5 gm/kg/week for 2 weeks followed by HA 40 grams every 7days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin
Description: Human albumin will be administered by intravenous infusion at a dose of 1.5 gm/kg/week for 2 weeks followed by HA 40 grams every 7days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midodrine
Description: Oral Midodrine will be given at a dose of 7.5 mg three times in a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical therapy (SMT)
Description: SMT will include nutritional support, rifaximin, lactulose or lactitol, diuretics, SBP prophylaxis with norfloxacin, restriction of sodium, multivitamins, and other supportive measures as deemed necessary. LVP will be done as needed. Patients on non-selective beta blockers will continue to do so with dose modifications/withdrawal as per Baveno VI guidelines.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical therapy (SMT)
Description: SMT will include nutritional support, rifaximin, lactulose or lactitol, diuretics, SBP prophylaxis with norfloxacin, restriction of sodium, multivitamins, and other supportive measures as deemed necessary. LVP will be done as needed. Patients on non-selective beta blockers will continue to do so with dose modifications/withdrawal as per Baveno VI guidelines.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard medical therapy (SMT)
Description: SMT will include nutritional support, rifaximin, lactulose or lactitol, diuretics, SBP prophylaxis with norfloxacin, restriction of sodium, multivitamins, and other supportive measures as deemed necessary. LVP will be done as needed. Patients on non-selective beta blockers will continue to do so with dose modifications/withdrawal as per Baveno VI guidelines.
Study: NCT03202927

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEGFILGRASTIM
Description: Pegfilgrastim is a covalent conjugate of recombinant methionyl human granulocyte colony-stimulating factor and monomethoxy polyethylene glycol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGFILGRASTIM
Description: Pegfilgrastim is a covalent conjugate of recombinant methionyl human granulocyte colony-stimulating factor and monomethoxy polyethylene glycol.
Study: NCT03248128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/VI via ELLIPTA DPI
Description: ELLIPTA DPI inhaler will contain two individual blister strips; the first strip will contain FF(50 or 100 mcg) and second strip will contain VI (25 mcg).
Study: NCT00289978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Description: Patients self-administered fingolimod 0.5 mg capsules orally once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients self-administered a fingolimod placebo capsule orally once daily.
Study: NCT01890538

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Administration of 100 mg dimenhydrinate intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 g piracetam intravenous
Study: NCT00626665

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tadalafil
Description: Tablets Tadalafil, 20 mg, alternate days, 6 weeks
Study: NCT03709030

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: magnetic resonance cholangiopancreatography (MRCP)
Description: magnetic resonance imaging of liver, gall bladder, pancreas
Study: NCT02285660

Intervention type: PROCEDURE
Group type: OTHER
Intervention: 4D PET-CT Scan

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Study: NCT03248128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/VI via ELLIPTA DPI
Description: ELLIPTA DPI inhaler will contain two individual blister strips; the first strip will contain FF(50 or 100 mcg) and second strip will contain VI (25 mcg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FF via ELLIPTA DPI
Description: ELLIPTA DPI inhaler will contain a single blister strip of FF (50 or 100 mcg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FF via ELLIPTA DPI
Description: ELLIPTA DPI inhaler will contain a single blister strip of FF (50 or 100 mcg).
Study: NCT03153605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Common toothpaste
Description: different toothpaste
Study: NCT01379313

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional I:E ratio
Description: conventional I:E ratio of 1:2 is applied.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional I:E ratio
Description: conventional I:E ratio of 1:2 is applied.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1:1 ratio
Description: I:E ratio of 1:1 is applied.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2:1 group
Description: Inverse I:E ratio of 2:1 is applied.
Study: NCT00758303

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for TRIA-662
Description: Matching Placebo for TRIA-662 taken 3 times a day
Study: NCT00784784

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluviral
Description: One dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanamivir
Description: 10 mg, OD, for duration of influenza season (10-23 weeks)
Study: NCT00221845

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACE Inhibition
Description: ACE inhibitor ramipril (6 mg/m²/day) will be given to all subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE Inhibition
Description: ACE inhibitor ramipril (6 mg/m²/day) will be given to all subjects.
Study: NCT01379313

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: external PEEP
Description: external positive end-expiratory pressure of 5 cmH2O is applied.
Study: NCT03135080

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long-Term HEAD START Training
Description: The Human Eyelid Analogue Device for Surgical Training And skill Reinforcement in Trachoma (HEAD START) is a surgical simulation device used to bridge the gap between classroom and live-surgery training specifically for trichiasis surgery. Long-term HEAD START practice will involve the following components, after completion of standard training (as described in the standard of care arm). Each week the participant will complete 2 surgeries on the HEAD START device. Monthly, the participant will send the accumulated cartridges to Addis Ababa for review by a senior trichiasis surgery trainer. The trainer will evaluate the cartridges and then will discuss his impression of the surgeries with the participant during a regular monthly call and note the findings. Practice will continue for 4-6 months, depending on the length of the rainy season and time of enrollment. At the end of the rainy season, an external examiner will evaluate the first 2 surgeries that the participant completes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: All participants will receive trichiasis surgery training following Orbis' standard training approach, with the inclusion of HEAD START training between classroom and live surgery training. At the end of the surgical training session, an independent examiner will evaluate all trainees using the World Health Organization's Final Assessment of Surgeons form, as part of standard practice. The examiner also will complete a standard questionnaire focusing on the specific skill level achieved for each of the critical aspects of TT surgery. This form will be completed for all trainees undergoing training this spring, regardless of whether they are part of the long-term HEAD START assessment program.
Study: NCT03171194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Mesenchymal Stem Cells (MSCs)
Description: Mesenchymal stromal/stem cells (MSCs) are cells that can be derived from umbilical cords, bone marrow, adipose tissue, and dental pulp, among other sites. MSCs have the ability to mediate a range of immuno-modulatory actions for both the innate and adaptive immune systems.
Study: NCT04384289

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nursing care based on the Transitonal Care Model
Description: Nursing care carried out in collaboration with a multidisciplinary team in line with Transitonal Care Model for elderly patients who have undergone open heart surgery
Study: NCT04200872

Intervention type: OTHER
Intervention: biological adjuvants
Description: patients with aseptic pseudarthrosis clinically treated with biological adjuvants

Intervention type: OTHER
Intervention: no biological adjuvants
Description: patients with aseptic pseudarthrosis clinically treated without biological adjuvants
Study: NCT02004769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab (Herceptin) will be administered at a loading dose of 8 mg/kg (on day 1) followed by 6mg/kg i.v. infusion every 3 weeks (q3w), until disease progress or intolerable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 60mg/m2 (on day 1) every 3 weeks for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine (Xeloda) 2000mg/m2d, d1-14, every 3 weeks until disease progress or intolerable toxicity.
Study: NCT03522532

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Amalgam placement
Description: Before the Amg was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tetric EvoCeram placement
Description: Before the TEC was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Beautifil placement
Description: Before the BF was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Zinc phosphate cement placement
Description: Before the ZPhC was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Zinc polycarboxylate cement placement
Description: Before the ZPoC was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
Study: NCT03486106

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Music will be provided via Spotify, which is an Internet streaming music service, and will be played through headphones; this way, no other individual in the operating room will be distracted or influenced by the patient's music selection.
Study: NCT03522532

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glass ionomer cement placement
Description: Before the GIC was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
Study: NCT03486106

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Headphones
Description: All participants will receive noise-cancelling wireless headphones that they will wear in the operating room during the procedure.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Headphones
Description: All participants will receive noise-cancelling wireless headphones that they will wear in the operating room during the procedure.
Study: NCT00221845

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intensified Blood Pressure Control
Description: Any antihypertensive drugs except ACE inhibitors and angiotensin receptor blockers will be allowed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensified Blood Pressure Control
Description: Any antihypertensive drugs except ACE inhibitors and angiotensin receptor blockers will be allowed.
Study: NCT02117830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal 25 mg capsules
Study: NCT00221845

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Add-on Angiotensin Receptor Blockade
Description: In patients who show persistent or breakthrough proteinuria at the end of the initial study period, telmisartan (50 mg/m²/day) will be added to the existing medication.
Study: NCT03486106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: All participants will receive intravenous doses of propofol; the timing and frequency of the doses will be given when the patient indicates (by squeezing a rubber duckie) that he/she wants sedation medication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: All participants will receive intravenous doses of propofol; the timing and frequency of the doses will be given when the patient indicates (by squeezing a rubber duckie) that he/she wants sedation medication.
Study: NCT00221845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Add-on Angiotensin Receptor Blockade
Description: In patients who show persistent or breakthrough proteinuria at the end of the initial study period, telmisartan (50 mg/m²/day) will be added to the existing medication.
Study: NCT01182129

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Nicotine pouch, 2.2 mg, single dose, 30 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Nicotine pouch, 2.2 mg, single dose, 30 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Chewing Gum, 4 mg, single dose, 30 minutes
Study: NCT03698240

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based program
Description: The program includes 9 mindfulness-based sessions for children and their parents.
Study: NCT02379910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM1030-CREAM or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM1030-CREAM or placebo
Study: NCT01828099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: Ceritinib was administered orally once-daily fasted at a dose of 750 mg capsules on a continuous dosing schedule.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed was administered at a dose of 500 mg/m\^2 as an intravenous (iv) infusion on Day 1 of each 21-day cycle
Study: NCT02379910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM1030-CREAM or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM1030-CREAM or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM1030-CREAM or placebo